Evonetix Ltd
United Kingdom
- Cambridge, England
- 10/02/2023
- Series B
- $24,000,000
We are a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible.
- Industry Research Services
- Website https://www.evonetix.com/
- LinkedIn https://www.linkedin.com/company/evonetix-ltd/
Related People
Colin McCrackenFounder
United Kingdom -
Cambridge, England
Accomplished life science Executive with global experience involving both start-up and growth organizations. Forthright, confident, creative, inspirational leader who is used to fast changing working environments. Consistent high performer, that works closely with people constantly striving to get things done. A clear thinker, that concentrates on the detail, bringing pragmatism and realism to all aspects of his work. A strong motivator and team builder.
Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)